Form 8-K · Current Report · Filed 2026-02-12
West Pharmaceutical Services Reports Strong 2025 Results and 2026 Guidance
West Pharmaceutical Services, Inc. reported a 7.5% increase in fourth-quarter net sales and 6.3% for the full year 2025, with organic growth of 3.3% and 4.3%, respectively. The company also announced a 12.1% increase in adjusted-diluted EPS for the fourth quarter and 8.0% for the full year. West introduced fiscal 2026 financial guidance with expected net sales growth of 4.6% to 6.5% and adjusted-diluted EPS growth of 7.7% to 12.5%.
- Filer
- West Pharmaceutical Services Inc. WST · NYSE
- Filed
- Accession
- 0000105770-26-000005
- CIK
- 0000105770
- Signal
- High impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$246.16
Next session
+1.8%
Since filing
+38.5%
Latest close
$340.96
What happened, not what will happen — closing prices around the filing date.
About West Pharmaceutical Services Inc.
West Pharmaceutical Services Inc. is a leading global provider of innovative solutions for injectable drug administration. The company specializes in designing and manufacturing packaging and delivery systems specifically for pharmaceuticals, biologics, and vaccines. West Pharmaceutical Services plays a crucial role in ensuring the safety and efficiency of drug delivery through its products, which include stoppers, seals, containers, and pre-fillable syringe systems. Catering to a diverse range of healthcare and pharmaceutical clients, the company's offerings are integral in the development and distribution of injectable therapies across various therapeutic categories, including oncology, diabetes, and infectious diseases. As a partner to some of the world's leading pharmaceutical companies, West Pharmaceutical Services contributes significantly to advancements in medical treatments and healthcare technologies globally. Its commitment to quality and innovation underscores its importance in the pharmaceutical supply chain and enhances drug efficacy, ultimately impacting patient care and treatment outcomes.
Never miss another WST filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.